Albert Català Temprano
Investigador
Research group
Professional network profiles
Last Publications
- Connor P, Ribeiro RC, Català-Temprano A, Norton A, Schündeln MM, Hasabou N, Delgado D, Heinloth AN, Hill JE, Gill SC, Bigirumurame T, Tasian SK and Locatelli F Gilteritinib and chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial Blood Advances . 10(13): 4786-4793.
- Alonso-Saladrigues A, Esperanza-Cebollada E, Vicente-Garces C, Pérez-Jaume S, Sánchez-Sierra N, Richarte M, Català-Temprano A, Crespo-Carrasco A, Dapena JL, Cuatrecasas E, Faura A, Ruiz-Cobo MA, Arqués L, Conde N, Andreu S, Isola I, Jordán-García I, Garcia-Rey E, Llanos C, Marsal-Ricoma J, Celis-Passini V, Camós-Guijosa M, Torrebadell-Burriel M, Vega-García N and Rives-Solà S Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy BONE MARROW TRANSPLANTATION . 61(6): 685-693.
- Vatovec T, Neehus AL, Jackson KJL, Avery DT, Bagaric I, Erazo L, Arango-Franco CA, Ogishi M, Ahmed SF, Cederholm A, Russell AJ, Della Mina E, Al-Rifai D, Bull R, Buetow L, Sobrino S, Zhang A, Wahlster L, Michelet M, Parvaneh N, Peel J, Barzaghi F, Leardini D, Philippot Q, Saettini F, Dutrieux J, de Muylder B, Vendemini F, Baccelli F, Català-Temprano A, Gambineri E, Veltroni M, Pandiarajan V, Aguilar Y, Haerynck F, Elliott M, Turville S, Brillot F, Khan T, Consonni F, Berteloot L, Sewell WA, Rao G, Largeaud L, Conti F, Roullion C, Masson C, Pegoraro F, Ye T, Joubran S, Villalpando E, Bessot B, Seeleuthner Y, Le Voyer T, Rosain J, Li H, Janda Z, Muratore E, Soudée C, Delabesse E, Goulvestre C, Shahrooei M, Puel A, André I, Bole-Feysot C, Abel L, Erlacher M, Béziat V, Lagresle-Peyrou C, Cheynier R, Six E, Marr N, Pasquet M, Alsina L, Goodnow CC, Landegren N, Aiuti A, Zhang P, Masetti R, Huang DT, Ma CS, Casanova JL, Sankaran VG, Bustamante J, Tangye SG and Bohlen J Somatic deficiency of the human E3 ubiquitin ligase CBL in leukocytes impairs B cell but not T cell development and function NATURE IMMUNOLOGY . 27(2): 308-322.
Projects
- Project name:
- Estudio multicéntrico fase II para evaluar la eficacia y seguridad de ARI-0001 en pacientes pediátricos (0-18 años) con leucemia linfoblástica aguda B CD19+ en primera recaída o refractariedad
- Leader
- Susana Rives Solà
- Funding entities:
- Fundacio Privada Bosch y Aymerich
- Code
- PCP00480
- Starting - finishing date:
- 2026 - 2027
- Project name:
- ADVANCED THERAPIES (RICORS-TERAV)
- Leader
- Susana Rives Solà
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- RD24/0014/0006
- Starting - finishing date:
- 2025 - 2027
- Project name:
- Estudio multicéntrico fase 2 en pacientes pediátricos (0-18 años) con leucemia linfoblástica aguda B CD19+ en recaída o refractaria
- Leader
- Susana Rives Solà
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- ICI21/00033
- Starting - finishing date:
- 2022 - 2026
News
-
Genetic events that could trigger leukemia in patients with a rare genetic disorder are deciphered
The study has been carried out thanks to advanced models of this genetic disorder generated by the researchers, which are presented as a key tool in its investigation.
